The presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation, Reform Act of 1995, relating to results from the Phase 3 clinical studies of Tofersen. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning.
Investors should consider this cautionary statement as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission.